Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Nucleophosmin 1 pseudogene 30 (NPM1P30)** is a genomic sequence in the human genome that resembles the functional **NPM1** gene but contains mutations or deletions (such as premature stop codons or frameshifts) that prevent it from encoding a functional protein[2][4]. As a pseudogene, NPM1P30 is generally considered a non-functional remnant of gene duplication or retrotransposition events. Unlike its parent gene NPM1—which encodes an essential nucleolar protein involved in ribosome biogenesis, the cell cycle, and multiple cancer-associated processes—NPM1P30 does not encode any active protein product and is not attributed with independent biological functions or therapeutic relevance[1][4]. There is no current evidence that NPM1P30 acts as a disease biomarker or a therapeutic drug target. Pseudogenes in general may sometimes regulate gene expression through RNA mechanisms (such as acting as microRNA decoys or regulators of parent gene transcripts), but specific regulatory roles for NPM1P30 have not been established in the literature and its disease or drug relevance is unreported[2][4]. **Key distinctions:** - NPM1P30 is not equivalent to the functional protein NPM1 (nucleophosmin 1), and does not share NPM1’s broad biological roles in ribosome assembly, genomic stability, cell cycle, or disease (especially hematologic malignancies)[1][3][5]. - Its designation as a pseudogene means NPM1P30 is not a member of major protein families or receptor classes relevant to drug targeting, such as G protein-coupled receptors, ion channels, enzymes, or transcription factors[4]. - No drugs or mechanisms of action are known to interact with NPM1P30, nor are there safety or biomarker considerations. If you intended to refer to the functional *NPM1* gene/protein (and not the pseudogene), that is a clinically significant oncogenic driver in acute myeloid leukemia, but "NPM1P30" is strictly a pseudogene and is not a therapeutic target[1][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on nucleophosmin 1 pseudogene 30 (NPM1P30).